Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
abemaciclib, Affordable, AstraZeneca, BACE, Basaglar, Biotec, calculate, candidate, CDK, Central, CHMP, classified, cleaving, consumer, Counsel, criteria, divest, etanercept, extra, Fast, fill, Flavor, FTC, FTUG, fulvestrant, GEJ, Hart, hearing, HEC, importing, injunctive, IRS, Kuang, leading, led, located, mCRC, modified, monetary, NAH, Nan, negligible, opportunity, Panacea, passed, Patient, Pharm, plant, plaque, prescription, Saavedra, selective, Sentinel, shutdown, skin, small, Spectrum, stomach, Track, tradename, Trulicity, unenforceable, unmet, Virbac, withdrew
Filing tables
Filing exhibits
- 10-Q Quarterly report
- 12 Statement Re: Computation of Ratio of Earnings to Fixed Charges
- 31.1 Rule 13A-14(A) Certification of John C. Lechleiter, Chairman, President, and CEO
- 31.2 Rule 13A-14(A) Certification of Derica W. Rice, Executive Vice President, CFO
- 32 Section 1350 Certification
- Download Excel data file
- View Excel data file
Related press release
LLY similar filings
Filing view
External links